Carregant...
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
BACKGROUND: HER2 is a therapeutic target for metastatic colorectal cancer (mCRC), as demonstrated in the pivotal HERACLES-A (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification) trial with trastuzumab and lapatinib. The aim of HERACLES-B trial is to assess the efficacy of the combinati...
Guardat en:
Publicat a: | ESMO Open |
---|---|
Autors principals: | , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artigo |
Idioma: | Inglês |
Publicat: |
BMJ Publishing Group
2020
|
Matèries: | |
Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7523198/ https://ncbi.nlm.nih.gov/pubmed/32988996 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2020-000911 |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|